复星医药1类新药获批临床,中生制药罗替高汀贴片获批上市,先声药业携手旺山旺水,德琪医药希维奥拓展香港市场

谈医说药
Dec 03

德琪医药:香港特别行政区政府卫生署已批准希维奥®(塞利尼索)用于治疗多发性骨髓瘤和复发性或难治性弥漫大B细胞淋巴瘤的两项补充新药上市申请。这一批准标志着公司在香港市场的进一步拓展,希维奥®将与硼替佐米和地塞米松联合使用,专门针对至少接受过一种治疗的成年多发性骨髓瘤患者。此外,希维奥®也将作为单药治疗方案,适用于经过至少两线系统性治疗且不符合造血干细胞移植的成人复发性或难治性弥漫大B细胞淋巴瘤患者。...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10